Back

Correlation Between Enzymatic and Non-Enzymatic Genes in Acinetobacter baumannii Isolates

Rahi, A. A.; Al-Hasnawy, H. H.

2024-10-28 genetic and genomic medicine
10.1101/2024.10.27.24316230 medRxiv
Show abstract

AbstractsO_ST_ABSBackgroundC_ST_ABSAcinetobacter baumannii is a multidrug-resistant bacterium responsible for severe infections, particularly in hospital settings. Its resistance is driven by enzymatic genes such as those encoding beta-lactamases and carbapenemases, which degrade antibiotics, and non-enzymatic genes that modify mechanisms like efflux pumps and membrane permeability, further enhancing its defence against treatments. Together, these factors allow A. baumannii to thrive in clinical environments, complicating infection management. ObjectiveThis study aimed to explore the relationships between beta-lactamases, carbapenemases, efflux pumps, and membrane permeability changes, to understand their collective contribution to A. baumanniis multidrug resistance. Materials and MethodsAmong 300 clinical isolates from urine, blood, wounds, and burns, 25 (8.33%) were identified as A. baumannii. These included 8% from urine, 12% from blood, and 40% each from wound and burn swabs. all specimens were taken from patients who have different symptoms in hospital of Al-Hilla Teaching Hospital/ Babylon. The research was carried out through the period January and June 2024. Bacterial identification was conducted using the VITEK-2 system and HI-Chromoagar(R) A. baumannii. Enzymatic genes were detected using conventional PCR, while non-enzymatic genes were analyzed via RT-qPCR. ResultsMolecular analysis revealed the presence of beta-lactamase (blaOXA-51, blaOXA-23) and metallo-beta-lactamase genes (blaVIM, blaIMP), with high antibiotic resistance rates. Gene expression analysis highlighted efflux pump upregulation (adeB) and altered permeability (CarO), reinforcing multidrug resistance mechanisms. ConclusionThe combined action of enzymatic and non-enzymatic resistance genes in A. baumannii presents a significant treatment challenge, necessitating multi-target therapeutic approaches.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Pathogens
53 papers in training set
Top 0.1%
14.3%
2
Journal of Hospital Infection
27 papers in training set
Top 0.1%
12.4%
3
PLOS ONE
4510 papers in training set
Top 19%
10.0%
4
Scientific Reports
3102 papers in training set
Top 19%
6.3%
5
Frontiers in Microbiology
375 papers in training set
Top 2%
3.9%
6
Journal of Global Antimicrobial Resistance
15 papers in training set
Top 0.1%
3.9%
50% of probability mass above
7
Antibiotics
32 papers in training set
Top 0.4%
3.6%
8
Genomics
60 papers in training set
Top 0.4%
3.2%
9
Cureus
67 papers in training set
Top 1%
3.0%
10
Biomedicines
66 papers in training set
Top 0.2%
3.0%
11
Microbiology Spectrum
435 papers in training set
Top 1%
2.9%
12
Archives of Clinical and Biomedical Research
28 papers in training set
Top 0.4%
2.1%
13
Frontiers in Molecular Biosciences
100 papers in training set
Top 1%
1.9%
14
JAC-Antimicrobial Resistance
13 papers in training set
Top 0.2%
1.8%
15
Heliyon
146 papers in training set
Top 2%
1.7%
16
Diagnostic Microbiology and Infectious Disease
21 papers in training set
Top 0.1%
1.7%
17
Journal of Medical Microbiology
20 papers in training set
Top 0.3%
1.5%
18
Antimicrobial Agents and Chemotherapy
167 papers in training set
Top 1%
1.3%
19
mSystems
361 papers in training set
Top 6%
1.2%
20
Journal of Medical Virology
137 papers in training set
Top 4%
0.7%
21
F1000Research
79 papers in training set
Top 5%
0.7%
22
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 6%
0.7%
23
Journal of Antimicrobial Chemotherapy
43 papers in training set
Top 0.5%
0.7%
24
International Journal of Molecular Sciences
453 papers in training set
Top 16%
0.7%
25
Epidemiology and Infection
84 papers in training set
Top 4%
0.6%
26
Open Forum Infectious Diseases
134 papers in training set
Top 3%
0.6%